Testing for and frequency of molecular alterations in patients with advanced NSCLC in Germany. Results from the prospective German registry CRISP (AIO-TRK-0315)

First‐linenab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: Final results of the NEPTUN study

“…Treatment options for patients with genetic aberrations have markedly improved following development of tyrosine kinase inhibitors. However, only a small proportion of patients currently benefits from targeted therapies against disease‐evoking alterations in genes like epidermal growth factor (EGFR), anaplastic lymphoma kinase (ALK), proto‐oncogene ROS1 or BRAF due to the relatively low mutation frequency of NSCLC 7,8 . In recent years, immunotherapy has become the standard of care for NSCLC patients, especially for patients with elevated (≥50%) PD‐L1 expression (pembrolizumab monotherapy 9,10 ) or independent of PD‐L1 expression level in combination with supportive chemotherapy as described in pivotal phase 3 trials 11 .…”

“…However, only a small proportion of patients currently benefits from targeted therapies against disease-evoking alterations in genes like epidermal growth factor (EGFR), anaplastic lymphoma kinase (ALK), proto-oncogene ROS1 or BRAF due to the relatively low mutation frequency of NSCLC. 7,8 In recent years, immunotherapy has become the standard of care for NSCLC patients, especially for patients with elevated (≥50%) PD-L1 expression (pembrolizumab monotherapy 9,10 ) or independent of PD-L1 expression level in combination with supportive chemotherapy as described in pivotal phase 3 trials. 11 Even though more recent treatments based on histology and molecular alterations including immune checkpoint inhibitors (ICI) are preferred as they are beneficial for patients with specific molecular subtypes, 12,13 chemotherapeutic combinations still play a major role in first-line treatment.…”

First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: Results of the NEPTUN study

“…Tyrosine kinase inhibitors have markedly improved treatment options for patients with genetic aberrations such as epidermal growth factor (EGFR) and anaplastic lymphoma kinase (ALKs). But only a small fraction of patients currently benefits from targeted therapies like EGFR‐, ALK‐, ROS1‐, or BRAF‐inhibitors due to the relatively low mutation frequency 4,5 . About one‐third of the NSCLC patients without targetable alteration show high programmed cell death‐ligand 1 (PD‐L1) expression ≥50% and therefore qualify for pembrolizumab monotherapy 6 ; the remaining majority is thus frequently treated with chemotherapy‐based therapy regimens.…”

“…But only a small fraction of patients currently benefits from targeted therapies like EGFR‐, ALK‐, ROS1‐, or BRAF‐inhibitors due to the relatively low mutation frequency. 4 , 5 About one‐third of the NSCLC patients without targetable alteration show high programmed cell death‐ligand 1 (PD‐L1) expression ≥50% and therefore qualify for pembrolizumab monotherapy 6 ; the remaining majority is thus frequently treated with chemotherapy‐based therapy regimens. According to current guidelines of the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) the nab ‐paclitaxel plus carboplatin combination ( nab ‐P/C) is a recommended standard first‐line treatment regimen for patients with advanced NSCLC without druggable alteration.…”